Cover Image
市場調查報告書

lentinan的中國市場分析

Investigation Report on China Lentinan Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334091
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
lentinan的中國市場分析 Investigation Report on China Lentinan Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 40 Pages
簡介

惡性癌症的發病數量全球各國都比3∼5%的速度增加,特別是年輕層的增加率日益升高。估計年度約300萬人,一分鐘便有6人發病。雖然治療上以化療為主流,但生物性多糖體(甜性藥) 的開發·使用也漸漸普及。Lentinan便是這種多糖體之一(免疫反應調節劑的一種),是擁有可延長生命、改善生活品質(QoL)、副作用小等潛在效果的抗癌劑。最初由日本開發,中國也在1988年上市,但直至近年由於價格居高不下而無法普及 。進入21世紀後國內已可生產,價格也開始下降,因此中國國內的lentinan市場開始擴大。2005年2億人民幣以下的銷售額,之後以11.3%的年平均成長率(CAGR)擴大,到2014年達到了4億7300萬人民幣。

本報告提供中國的lentinan的市場相關分析,提供您整體市場規模趨勢(過去5年份)和國內價格趨勢,各企業·給藥型態別的市場佔有率,主要製造商簡介,未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 lentinan的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的lentinan市場概況

  • 中國國內的lentinan的專利申請·認證情形
  • 主要製造商
  • 市場規模

第3章 lentinan銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的lentinan市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (以銷售額為準)
  • 市場佔有率 (以銷售量為準)

第5章 中國的lentinan市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (以銷售額為準)
  • 各劑型的市場佔有率 (以銷售量為準)

第6章 lentinan的醫院用標準價格

  • Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd
  • Nanjing Luye Sike Pharma Co., Ltd (商標名:TIANDIXIN)
  • Kanion Pharmaceutical
  • Apeloa Kangyu
  • Chuang Li Yao Ye
  • JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory

第7章 中國國內的lentinan的主要製造商 (過去5年份)

  • Kaifeng Pharmaceutical (Group) Co., Ltd
  • Chuang Li Yao Ye
  • JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory
  • Kanion Pharmaceutical
  • Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd

第8章 中國的lentinan市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1507252

Currently, the incidence of malignant cancer is growing at 3%-5% with more and more younger people. The number of new cases of cancer exceeds 3 million each year with six confirmed cases every one minute. And bad living habits and changed environment have become the main risk factors of cancer.

Carbohydrate drug is the bioactive carbohydrate and its derivatives isolated from animals, plants, microbes and sea creatures. The diversity of carbohydrate structure determines the diversity of carbohydrate drug's bioactivity. One category of carbohydrate drugs is the immunoregulatory anti-tumor polysaccharide isolated from plants and microbes. Although chemotherapy drugs are the most common drugs for malignant cancer in the clinic, polysaccharide is with no side effects. Therefore, more and more polysaccharide drugs are used for the treatment or assistive treatment of tumor. Currently, fungi polysaccharide like lentinan, schizophyllan, ganoderan and pachymaran as well as higher plants polysaccharide such as astragalus polysaccharide and panaxan have been widely used in the clinic as immunomodulators and anti-tumor drugs.

As an intravenous biological response modifier, lentinan features potent antitumor effects, remarkably prolonged life, improved life quality and mild side effects. First developed by Japan, lentinan was approved to enter China in 1988. Although the practical use has confirmed lentinan's efficacy, its market size has been limited due to its high price.

After entering the 21st century, lentinan has become able to be produced domestically at a relatively low price. Therefore, its market size grows at an increasing rate, annual sales value rising from less than CNY 200 million in 2005 to CNY 473 million in 2014 and CAGR during this period reaching 11.3%. JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory, Chuang Li Yao Ye, Kanion Pharmaceutical, Nanjing Luye Sike Pharma Co., Ltd and Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory had the largest market share of about 39% for sales value in 2014.

With worsened environmental pollution and lifestyle change brought about by economic development, the incidence of cancer keeps growing. Therefore, the market size of lentinan in China is expected to grow too.

Readers can get at least the following information from this report:

  • market size of lentinan in China
  • competitive landscape of lentinan in Chinese market
  • price of lentinan made by different enterprises in China
  • market outlook of lentinan in China

The author suggests the following groups of people purchase this report:

  • manufacturers of immunomodulator
  • manufacturers of antitumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Lentinan

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Lentinan in China

  • 2.1. Patent and Approval Status of Lentinan in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Lentinan in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Lentinan in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Lentinan in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Lentinan in Chinese Hospitals in 2014

  • 6.1. Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd
  • 6.2. Nanjing Luye Sike Pharma Co., Ltd (Trade Name: TIANDIXIN)
  • 6.3. Kanion Pharmaceutical
  • 6.4. Apeloa Kangyu
  • 6.5. Chuang Li Yao Ye
  • 6.6. JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory

7. Major Manufacturers of Lentinan in Chinese Market, 2010-2014

  • 7.1. Kaifeng Pharmaceutical (Group) Co., Ltd
  • 7.2. Chuang Li Yao Ye
  • 7.3. JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory
  • 7.4. Kanion Pharmaceutical
  • 7.5. Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd

8. Market Outlook of Lentinan in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Chart of Selected Charts

  • Chart Patent Status of Lentinan in China
  • Chart Approval Information of Lentinan in China
  • Chart Sales Status of Lentinan in China
  • Chart Sales Value of Lentinan in China, 2010-2014
  • Chart Sales Value of Lentinan in Some Regions in China, 2010-2014
  • Chart Sales Volume of Lentinan in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Lentinan for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by Nanjing Luye Sike in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by Shanxi Zhendong Taisheng in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by Kanion in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by Chuang Li in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Made by Other Enterprises in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Injections in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Lentinan Capsules in China, 2010-2014
  • Chart Price of Lentinan Made by Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lentinan Made by Nanjing Luye Sike Pharma Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lentinan Made by Kanion Pharmaceutical in Some Chinese Cities in 2014
  • Chart Price of Lentinan Made by Apeloa Kangyu in Some Chinese Cities in 2014
  • Chart Price of Lentinan Made by Chuang Li Yao Ye in Some Chinese Cities in 2014
  • Chart Price of Lentinan Made by JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory in Some Chinese Cities in 2014
Back to Top